Jiangsu Gdk Biological Technology Co., Ltd (SHA:688670)
China · Delayed Price · Currency is CNY 15.93
-0.38 (-2.33%)
Sep 2, 2026, 3:00 PM CST
SHA:688670 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 110.27 | 112.88 | 80.8 | 134.59 | 318.49 | 390.56 |
Other Revenue | - | - | - | - | - | 1.71 |
| 110.27 | 112.88 | 80.8 | 134.59 | 318.49 | 392.27 | |
Revenue Growth | 36.07% | 39.70% | -39.96% | -57.74% | -18.81% | -33.41% |
Cost of Revenue | 62.18 | 58.91 | 51.87 | 86.29 | 87.41 | 114.52 |
Gross Profit | 48.09 | 53.97 | 28.93 | 48.3 | 231.07 | 277.75 |
Selling, General & Admin | 142.01 | 147.43 | 117.06 | 134.1 | 166.35 | 163.09 |
Research & Development | 91.08 | 91.78 | 33.61 | 15.47 | 32.41 | 35.26 |
Other Operating Expenses | 1.91 | 2 | 1.93 | 1.35 | 2.84 | 3.56 |
Operating Expenses | 239.22 | 245.44 | 155.27 | 139.66 | 202.75 | 203.18 |
Operating Income | -191.13 | -191.47 | -126.34 | -91.36 | 28.32 | 74.58 |
Interest Expense | -1.28 | -1.28 | -1.6 | -1.9 | -1.28 | -9.85 |
Interest & Investment Income | 5.12 | 6.78 | 12.96 | 15.15 | 17.53 | 7.69 |
Currency Exchange Gain (Loss) | - | - | - | - | 0 | - |
Other Non Operating Income (Expenses) | -1.48 | -4.71 | -3.81 | -0.9 | -0.02 | -0.01 |
EBT Excluding Unusual Items | -188.77 | -190.67 | -118.79 | -79.01 | 44.55 | 72.4 |
Gain (Loss) on Sale of Investments | -0.26 | -0.39 | 0.17 | -0.15 | -1.74 | 2.31 |
Gain (Loss) on Sale of Assets | -0.3 | -0.3 | -0.95 | - | 0.23 | -0.05 |
Asset Writedown | -8.89 | -6.67 | - | -0.24 | -3.29 | -3.75 |
Other Unusual Items | 0.81 | 0.81 | 3.74 | -7.18 | 8.66 | 13.09 |
Pretax Income | -197.4 | -197.21 | -115.83 | -86.57 | 48.41 | 84 |
Income Tax Expense | -7.51 | -18.75 | -22.25 | -15.58 | 6.86 | 1.54 |
Net Income | -189.88 | -178.46 | -93.58 | -70.99 | 41.54 | 82.46 |
Net Income to Common | -189.88 | -178.46 | -93.58 | -70.99 | 41.54 | 82.46 |
Net Income Growth | - | - | - | - | -49.62% | -46.79% |
Shares Outstanding (Basic) | 123 | 123 | 123 | 122 | 122 | 105 |
Shares Outstanding (Diluted) | 123 | 123 | 123 | 122 | 122 | 105 |
Shares Change | 0.18% | -0.05% | 0.60% | 0.17% | 16.43% | 13.67% |
EPS (Basic) | -1.54 | -1.45 | -0.76 | -0.58 | 0.34 | 0.79 |
EPS (Diluted) | -1.54 | -1.45 | -0.76 | -0.58 | 0.34 | 0.79 |
EPS Growth | - | - | - | - | -56.73% | -53.19% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -158.13 | -201.42 | -169.87 | 26.9 | -129.58 | -282.46 |
Free Cash Flow Per Share | -1.28 | -1.64 | -1.38 | 0.22 | -1.06 | -2.69 |
Dividend Per Share | - | - | - | - | 0.143 | 0.357 |
Dividend Growth | - | - | - | - | -59.98% | - |
Gross Margin | 43.61% | 47.81% | 35.80% | 35.89% | 72.55% | 70.81% |
Operating Margin | -173.33% | -169.62% | -156.35% | -67.88% | 8.89% | 19.01% |
Profit Margin | -172.20% | -158.10% | -115.82% | -52.74% | 13.04% | 21.02% |
Free Cash Flow Margin | -143.40% | -178.43% | -210.22% | 19.99% | -40.69% | -72.01% |
EBITDA | -165.4 | -162.61 | -96.34 | -61.49 | 58.08 | 102.65 |
EBITDA Margin | -149.99% | -144.05% | -119.23% | -45.68% | 18.24% | 26.17% |
D&A For EBITDA | 25.74 | 28.86 | 30 | 29.87 | 29.76 | 28.08 |
EBIT | -191.13 | -191.47 | -126.34 | -91.36 | 28.32 | 74.58 |
EBIT Margin | -173.33% | -169.62% | -156.35% | -67.88% | 8.89% | 19.01% |
Effective Tax Rate | - | - | - | - | 14.18% | 1.83% |
Revenue as Reported | 112.88 | 112.88 | 80.8 | 134.59 | 318.49 | 392.27 |